A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06560645 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Advanced Solid Tumor
Metastatic Solid Tumor
Non-small Cell Lung Carcinoma
SMARCA4 Mutation
Esophageal Adenocarcinoma
Esophageal Squamous Cell Carcinoma
Gastric Adenocarcinoma
Gastric Squamous Cell Carcinoma
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Squamous Cell Carcinoma

Interventions

DRUG: PRT7732

Sponsor

Prelude Therapeutics